No material corporate announcements were identified for Gilead Sciences Inc. (GILD) in the 30 days preceding this report. Three consecutive briefings — dated 2026-09-11, 2026-09-19, and 2026-09-27 — each noted the absence of discrete news events, with analysis in each case anchored to verified financial filings and transaction records [Brief - 2026-09-27] [Brief - 2026-09-19] [Brief - 2026-09-11].
As of the quarter ended 2026-06-30, Gilead reported trailing twelve-month revenue of $30.46 billion, reflecting year-over-year growth of 10.2%. Gross margin stood at 64.95%, while the operating margin was -8.20% and the net margin was -10.64%, resulting in a net loss of $3.24 billion on a TTM basis. EPS declined year-over-year by 641.67%, rendering the P/E ratio not applicable. Market capitalisation was approximately $179.6 billion. Cash on hand was $3.18 billion against total debt of $28.66 billion [SEC 10-Q - GILD - 2026-06-30].
Insider activity in the 30-day window to October 2026 comprised 18 transactions with a net selling direction, totalling a net disposal value of approximately $3.09 million [SEC Form 4 - GILD - 2026-10]. On the institutional side, four significant new positions were opened during the most recent 13F reporting period: Citadel (Ken Griffin), Millennium (Izzy Englander), AQR Capital (Cliff Asness), and Bridgewater (Ray Dalio) each initiated new holdings in GILD [SEC 13F - Citadel - Q3 2026] [SEC 13F - Millennium - Q3 2026] [SEC 13F - AQR Capital - Q3 2026] [SEC 13F - Bridgewater - Q3 2026].
The prevailing macro environment features a 10-year US Treasury yield of 5.24% and a 2-year yield of 4.78%, producing a normal yield curve spread of 46 basis points [FRED DGS10] [FRED DGS2]. The simultaneous initiation of new positions by multiple institutional managers — including four distinct firms of material scale — constitutes the primary data event triggering this report.